Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HALOZYME THERAPEUTICS, INC.

(HALO)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
57.26 USD   +0.37%
11/28Halozyme Therapeutics Shares Rise After Wells Fargo Initiates Coverage at Overweight
MT
11/28Wells Fargo Starts Halozyme Therapeutics at Overweight With $65
MT
11/22JPMorgan Chase Adjusts Price Target on Halozyme Therapeutics to $54 From $53, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Halozyme Therapeutics Says Phase 3 Study Evaluating Formulation of Tecentriq with Enhanze Met Co-Primary Endpoints

08/02/2022 | 03:28am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
HALOZYME THERAPEUTICS, INC. 0.37% 57.26 Delayed Quote.42.40%
ROCHE HOLDING AG -0.47% 307.8 Delayed Quote.-18.43%
All news about HALOZYME THERAPEUTICS, INC.
11/28Halozyme Therapeutics Shares Rise After Wells Fargo Initiates Coverage at Overweight
MT
11/28Wells Fargo Starts Halozyme Therapeutics at Overweight With $65
MT
11/22JPMorgan Chase Adjusts Price Target on Halozyme Therapeutics to $54 From $53, Maintains..
MT
11/13Halozyme Therapeutics : Corporate Presentation
PU
11/09Sector Update: Health Care Stocks Dragged Lower in Wednesday Selloff
MT
11/09Sector Update: Health Care Stocks Hanging to Small Gains
MT
11/09JMP Securities Adjusts Price Target on Halozyme Therapeutics to $62 From $60, Maintains..
MT
11/09Halozyme to Participate in Upcoming Investor Conferences
PR
11/08Halozyme Therapeutics Q3 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
MT
11/08Transcript : Halozyme Therapeutics, Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
More news
Analyst Recommendations on HALOZYME THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 676 M - -
Net income 2022 189 M - -
Net cash 2022 80,9 M - -
P/E ratio 2022 42,3x
Yield 2022 -
Capitalization 7 742 M 7 742 M -
EV / Sales 2022 11,3x
EV / Sales 2023 8,18x
Nbr of Employees 145
Free-Float 98,9%
Chart HALOZYME THERAPEUTICS, INC.
Duration : Period :
Halozyme Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HALOZYME THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 57,26 $
Average target price 53,22 $
Spread / Average Target -7,05%
EPS Revisions
Managers and Directors
Helen I. Torley President, Chief Executive Officer & Director
Nicole LaBrosse Executive Director & Controller
Connie L. Matsui Chairman
Michael J. LaBarre Chief Technical Officer & Senior Vice President
Steve Knowles Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HALOZYME THERAPEUTICS, INC.42.40%7 714
VERTEX PHARMACEUTICALS44.08%81 199
REGENERON PHARMACEUTICALS, INC.16.56%78 615
BIONTECH SE-35.21%39 760
WUXI APPTEC CO., LTD.-34.22%31 776
GENMAB A/S20.91%28 866